AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,336,000 | -5.4% | 53,999 | +8.3% | 0.00% | – |
| Q2 2023 | $1,412,000 | +36.8% | 49,869 | +11.0% | 0.00% | – |
| Q1 2023 | $1,032,000 | -19.2% | 44,923 | -1.3% | 0.00% | – |
| Q4 2022 | $1,278,000 | +8.8% | 45,501 | +9.5% | 0.00% | – |
| Q3 2022 | $1,175,000 | +66.0% | 41,541 | +30.1% | 0.00% | – |
| Q2 2022 | $708,000 | -3.7% | 31,926 | +26.2% | 0.00% | – |
| Q1 2022 | $735,000 | -21.8% | 25,290 | -11.5% | 0.00% | – |
| Q4 2021 | $940,000 | -33.3% | 28,565 | -6.4% | 0.00% | – |
| Q3 2021 | $1,410,000 | +4.6% | 30,532 | +24.8% | 0.00% | – |
| Q2 2021 | $1,348,000 | -35.5% | 24,466 | -39.6% | 0.00% | -100.0% |
| Q1 2021 | $2,091,000 | +25.7% | 40,490 | +5.5% | 0.00% | – |
| Q4 2020 | $1,663,000 | -60.6% | 38,380 | -68.2% | 0.00% | -100.0% |
| Q3 2020 | $4,222,000 | -22.2% | 120,639 | +18.9% | 0.00% | 0.0% |
| Q2 2020 | $5,425,000 | +61.9% | 101,430 | +7.4% | 0.00% | 0.0% |
| Q1 2020 | $3,350,000 | -23.3% | 94,419 | +3.2% | 0.00% | 0.0% |
| Q4 2019 | $4,368,000 | +1025.8% | 91,455 | +665.2% | 0.00% | – |
| Q3 2019 | $388,000 | -88.6% | 11,952 | -82.5% | 0.00% | -100.0% |
| Q2 2019 | $3,397,000 | -27.9% | 68,127 | -2.5% | 0.00% | -50.0% |
| Q1 2019 | $4,714,000 | -19.6% | 69,907 | -45.0% | 0.00% | -33.3% |
| Q4 2018 | $5,865,000 | -52.1% | 127,200 | -19.8% | 0.00% | -40.0% |
| Q3 2018 | $12,232,000 | -7.7% | 158,610 | +0.8% | 0.01% | -16.7% |
| Q2 2018 | $13,258,000 | -40.1% | 157,400 | -41.8% | 0.01% | -40.0% |
| Q1 2018 | $22,126,000 | +23.1% | 270,548 | -13.9% | 0.01% | +25.0% |
| Q4 2017 | $17,967,000 | +195.3% | 314,261 | +244.8% | 0.01% | +166.7% |
| Q3 2017 | $6,084,000 | +1194.5% | 91,155 | +898.3% | 0.00% | – |
| Q2 2017 | $470,000 | +24.3% | 9,131 | +40.8% | 0.00% | – |
| Q1 2017 | $378,000 | +320.0% | 6,483 | +199.9% | 0.00% | – |
| Q4 2016 | $90,000 | -15.1% | 2,162 | +7.5% | 0.00% | – |
| Q3 2016 | $106,000 | -42.1% | 2,011 | -53.9% | 0.00% | – |
| Q2 2016 | $183,000 | +1.1% | 4,364 | -2.3% | 0.00% | – |
| Q1 2016 | $181,000 | +2.8% | 4,465 | +65.0% | 0.00% | – |
| Q4 2015 | $176,000 | -2.2% | 2,706 | +5.5% | 0.00% | – |
| Q3 2015 | $180,000 | -4.8% | 2,566 | +50.9% | 0.00% | – |
| Q2 2015 | $189,000 | +30.3% | 1,701 | +10.5% | 0.00% | – |
| Q1 2015 | $145,000 | +123.1% | 1,539 | +167.7% | 0.00% | – |
| Q4 2014 | $65,000 | -89.6% | 575 | -94.3% | 0.00% | – |
| Q3 2014 | $623,000 | +6822.2% | 10,150 | +4975.0% | 0.00% | – |
| Q2 2014 | $9,000 | -98.6% | 200 | -98.8% | 0.00% | – |
| Q1 2014 | $634,000 | -25.1% | 16,200 | -46.5% | 0.00% | -100.0% |
| Q3 2013 | $847,000 | – | 30,270 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |